Therapeutic Nuclear Medicines Market Set for Significant Expansion - Expected to Hit USD 7.46 Billion by 2031 at 10.4% CAGR

QY Research has recently published a report, titled "Therapeutic Nuclear Medicines Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". The global Therapeutic Nuclear Medicines market is comprehensively analyzed in the report with the main objective of providing accurate market data and useful recommendations to help players to gain strong growth in future. The report is compiled by subject matter experts and experienced market analysts, which makes it highly authentic and reliable. Readers are provided with deep analysis of historical and future market scenarios to get sound understanding of market competition and other important aspects. The report offers exhaustive research on market dynamics, key segments, leading players, and different regional markets. It is a complete package of thorough analysis and research on the global Therapeutic Nuclear Medicines market.

The global market for Therapeutic Nuclear Medicines was estimated to be worth US$ 3854 million in 2024 and is forecast to a readjusted size of US$ 7460 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/pharma-healthcare-therapeutic-nuclear-medicines-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Therapeutic nuclear medicines are a class of pharmaceuticals that utilize radioactive isotopes to deliver cytotoxic radiation directly to diseased tissues, particularly tumors. These agents combine radioisotopes with targeting molecules-such as peptides, antibodies, or small ligands-to emit alpha, beta, or Auger electrons with high precision. This targeted radiation induces cell death while minimizing damage to surrounding healthy tissues. Therapeutic radiopharmaceuticals are especially promising for cancers that are inoperable or unresponsive to conventional therapies, such as prostate cancer and neuroendocrine tumors. With the rapid advances in precision medicine and molecular imaging, this category is emerging as a pivotal frontier in personalized oncology, offering both clinical efficacy and strong commercial potential.

Driven by the advancement of precision medicine, therapeutic nuclear medicines are gaining momentum as a cornerstone of theranostics. Collaborations between major pharmaceutical companies and radioisotope suppliers are accelerating the development of novel radioligands, while regulatory approvals of breakthrough products are expanding the treatment landscape and attracting investor interest. Government policies supporting isotope production, nuclear logistics, and expedited approvals are further unlocking industry potential and enabling faster translation from R&D to clinical practice.

Despite their clinical promise, therapeutic radiopharmaceuticals face considerable industrial barriers. Radioisotope sourcing is restricted due to national strategic controls, and the supply chain is tightly regulated. Manufacturing and distribution require strict compliance with radiation safety, GMP standards, and cold-chain logistics, resulting in high operational thresholds. Additionally, limited awareness among physicians and patients leads to longer adoption cycles, making education and commercialization efforts critical for new entrants.

As oncology moves toward molecular subtyping and individualized treatment, demand is rising for therapies that offer high efficacy with minimal side effects. Therapeutic nuclear medicines are increasingly incorporated into treatment protocols for advanced-stage cancers. The integration of radiotherapy and diagnostics within hospital platforms is enhancing institutional acceptance and adoption. Meanwhile, global pharmaceutical leaders are accelerating the development of next-generation radiopharmaceuticals across multiple indications, driving broader clinical penetration and application scenarios.

Drivers and Restraints-

The report explains the drivers shaping the future of the Therapeutic Nuclear Medicines market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global Therapeutic Nuclear Medicines market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global Therapeutic Nuclear Medicines market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

The competitive landscape of the global Therapeutic Nuclear Medicines market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Therapeutic Nuclear Medicines market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Therapeutic Nuclear Medicines Market Research Report:

Cardinal Health
GE Healthcare
Lantheus Medical Imaging
Bayer
Eli Lilly
Bracco Imaging
Curium Pharma
Jubilant Pharmova
Aurobindo Pharma
Novartis
Siemens
NTP Radioisotopes
ANSTO
Polatom
China Isotope & Radiation
Dongcheng Pharma
Saide Bio

The report offers great insights into important segments of the global Therapeutic Nuclear Medicines market while concentrating on their CAGR, market size, market share, and future growth potential. The global Therapeutic Nuclear Medicines market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Therapeutic Nuclear Medicines market.

Details of Therapeutic Nuclear Medicines Market Segmentation: -

Segment by Type:

Radium-223
Lutetium-177
Iodine-131
Other

Segment by Application:

Thyroid
Bone Metastasis
Lymphoma
Other

Research Methodology

This report has been compiled using latest primary and secondary research methodologies such as data triangulation, qualitative and quantitative analysis, and top-down and bottom-up approaches. The researchers also referred to reliable secondary sources for collecting important data and statistics. All the findings of the research study have been verified and revalidated with the help of authentic primary sources.

The researchers create a unique model and customize it for each research study. Their market forecasts are based on the industry-best combination of domain expertise, industry knowledge and experience, technological analysis, and economic tools. Technological market models are generally adopted for long-term market forecasting, whereas econometric models are adopted for short-term forecasting. The researchers were provided with advanced analysis tools at the time of the preparation of the report.

Report Objectives

(1) To carefully analyze and estimate the size of the global Therapeutic Nuclear Medicines market

(2) To clearly segment the global Therapeutic Nuclear Medicines market and estimate the market size of the segments

(3) To provide details about key strategies adopted by leading players of the global Therapeutic Nuclear Medicines market

(4) To help readers understand current and future market scenarios

(5) To provide information about latest trends of the global Therapeutic Nuclear Medicines market and its key segments

(6) To assess the contribution of each region or country to the global Therapeutic Nuclear Medicines market

(7) To provide information on important drivers, restraints, and opportunities of the global Therapeutic Nuclear Medicines market

(8) To accurately calculate the market shares of key segments, regions, and companies in the global Therapeutic Nuclear Medicines market

Request Pre-Order Enquiry or Customized Research on This Report: https://www.qyresearch.in/pre-order-inquiry/pharma-healthcare-therapeutic-nuclear-medicines-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content

1 Market Overview
1.1 Therapeutic Nuclear Medicines Product Introduction
1.2 Global Therapeutic Nuclear Medicines Market Size Forecast
1.2.1 Global Therapeutic Nuclear Medicines Sales Value (2020-2031)
1.2.2 Global Therapeutic Nuclear Medicines Sales Volume (2020-2031)
1.2.3 Global Therapeutic Nuclear Medicines Sales Price (2020-2031)
1.3 Therapeutic Nuclear Medicines Market Trends & Drivers
1.3.1 Therapeutic Nuclear Medicines Industry Trends
1.3.2 Therapeutic Nuclear Medicines Market Drivers & Opportunity
1.3.3 Therapeutic Nuclear Medicines Market Challenges
1.3.4 Therapeutic Nuclear Medicines Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Therapeutic Nuclear Medicines Players Revenue Ranking (2024)
2.2 Global Therapeutic Nuclear Medicines Revenue by Company (2020-2025)
2.3 Global Therapeutic Nuclear Medicines Players Sales Volume Ranking (2024)
2.4 Global Therapeutic Nuclear Medicines Sales Volume by Company Players (2020-2025)
2.5 Global Therapeutic Nuclear Medicines Average Price by Company (2020-2025)
2.6 Key Manufacturers Therapeutic Nuclear Medicines Manufacturing Base and Headquarters
2.7 Key Manufacturers Therapeutic Nuclear Medicines Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Therapeutic Nuclear Medicines
2.9 Therapeutic Nuclear Medicines Market Competitive Analysis
2.9.1 Therapeutic Nuclear Medicines Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Therapeutic Nuclear Medicines Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Nuclear Medicines as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Radium-223
3.1.2 Lutetium-177
3.1.3 Iodine-131
3.1.4 Other
3.2 Global Therapeutic Nuclear Medicines Sales Value by Type
3.2.1 Global Therapeutic Nuclear Medicines Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Therapeutic Nuclear Medicines Sales Value, by Type (2020-2031)
3.2.3 Global Therapeutic Nuclear Medicines Sales Value, by Type (%) (2020-2031)
3.3 Global Therapeutic Nuclear Medicines Sales Volume by Type
3.3.1 Global Therapeutic Nuclear Medicines Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Therapeutic Nuclear Medicines Sales Volume, by Type (2020-2031)
3.3.3 Global Therapeutic Nuclear Medicines Sales Volume, by Type (%) (2020-2031)
3.4 Global Therapeutic Nuclear Medicines Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Thyroid
4.1.2 Bone Metastasis
4.1.3 Lymphoma
4.1.4 Other
4.2 Global Therapeutic Nuclear Medicines Sales Value by Application
4.2.1 Global Therapeutic Nuclear Medicines Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Therapeutic Nuclear Medicines Sales Value, by Application (2020-2031)
4.2.3 Global Therapeutic Nuclear Medicines Sales Value, by Application (%) (2020-2031)
4.3 Global Therapeutic Nuclear Medicines Sales Volume by Application
4.3.1 Global Therapeutic Nuclear Medicines Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Therapeutic Nuclear Medicines Sales Volume, by Application (2020-2031)
4.3.3 Global Therapeutic Nuclear Medicines Sales Volume, by Application (%) (2020-2031)
4.4 Global Therapeutic Nuclear Medicines Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Therapeutic Nuclear Medicines Sales Value by Region
5.1.1 Global Therapeutic Nuclear Medicines Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Therapeutic Nuclear Medicines Sales Value by Region (2020-2025)
5.1.3 Global Therapeutic Nuclear Medicines Sales Value by Region (2026-2031)
5.1.4 Global Therapeutic Nuclear Medicines Sales Value by Region (%), (2020-2031)
5.2 Global Therapeutic Nuclear Medicines Sales Volume by Region
5.2.1 Global Therapeutic Nuclear Medicines Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Therapeutic Nuclear Medicines Sales Volume by Region (2020-2025)
5.2.3 Global Therapeutic Nuclear Medicines Sales Volume by Region (2026-2031)
5.2.4 Global Therapeutic Nuclear Medicines Sales Volume by Region (%), (2020-2031)
5.3 Global Therapeutic Nuclear Medicines Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Therapeutic Nuclear Medicines Sales Value, 2020-2031
5.4.2 North America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Therapeutic Nuclear Medicines Sales Value, 2020-2031
5.5.2 Europe Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Therapeutic Nuclear Medicines Sales Value, 2020-2031
5.6.2 Asia Pacific Therapeutic Nuclear Medicines Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Therapeutic Nuclear Medicines Sales Value, 2020-2031
5.7.2 South America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Therapeutic Nuclear Medicines Sales Value, 2020-2031
5.8.2 Middle East & Africa Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value and Sales Volume
6.2.1 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.2.2 Key Countries/Regions Therapeutic Nuclear Medicines Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.3.2 United States Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.4.2 Europe Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.5.2 China Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.5.3 China Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.6.2 Japan Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.7.2 South Korea Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.8.2 Southeast Asia Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Therapeutic Nuclear Medicines Sales Value, 2020-2031
6.9.2 India Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
6.9.3 India Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Cardinal Health
7.1.1 Cardinal Health Company Information
7.1.2 Cardinal Health Introduction and Business Overview
7.1.3 Cardinal Health Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Cardinal Health Therapeutic Nuclear Medicines Product Offerings
7.1.5 Cardinal Health Recent Development
7.2 GE Healthcare
7.2.1 GE Healthcare Company Information
7.2.2 GE Healthcare Introduction and Business Overview
7.2.3 GE Healthcare Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 GE Healthcare Therapeutic Nuclear Medicines Product Offerings
7.2.5 GE Healthcare Recent Development
7.3 Lantheus Medical Imaging
7.3.1 Lantheus Medical Imaging Company Information
7.3.2 Lantheus Medical Imaging Introduction and Business Overview
7.3.3 Lantheus Medical Imaging Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Lantheus Medical Imaging Therapeutic Nuclear Medicines Product Offerings
7.3.5 Lantheus Medical Imaging Recent Development
7.4 Bayer
7.4.1 Bayer Company Information
7.4.2 Bayer Introduction and Business Overview
7.4.3 Bayer Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Bayer Therapeutic Nuclear Medicines Product Offerings
7.4.5 Bayer Recent Development
7.5 Eli Lilly
7.5.1 Eli Lilly Company Information
7.5.2 Eli Lilly Introduction and Business Overview
7.5.3 Eli Lilly Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Eli Lilly Therapeutic Nuclear Medicines Product Offerings
7.5.5 Eli Lilly Recent Development
7.6 Bracco Imaging
7.6.1 Bracco Imaging Company Information
7.6.2 Bracco Imaging Introduction and Business Overview
7.6.3 Bracco Imaging Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Bracco Imaging Therapeutic Nuclear Medicines Product Offerings
7.6.5 Bracco Imaging Recent Development
7.7 Curium Pharma
7.7.1 Curium Pharma Company Information
7.7.2 Curium Pharma Introduction and Business Overview
7.7.3 Curium Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Curium Pharma Therapeutic Nuclear Medicines Product Offerings
7.7.5 Curium Pharma Recent Development
7.8 Jubilant Pharmova
7.8.1 Jubilant Pharmova Company Information
7.8.2 Jubilant Pharmova Introduction and Business Overview
7.8.3 Jubilant Pharmova Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Jubilant Pharmova Therapeutic Nuclear Medicines Product Offerings
7.8.5 Jubilant Pharmova Recent Development
7.9 Aurobindo Pharma
7.9.1 Aurobindo Pharma Company Information
7.9.2 Aurobindo Pharma Introduction and Business Overview
7.9.3 Aurobindo Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Aurobindo Pharma Therapeutic Nuclear Medicines Product Offerings
7.9.5 Aurobindo Pharma Recent Development
7.10 Novartis
7.10.1 Novartis Company Information
7.10.2 Novartis Introduction and Business Overview
7.10.3 Novartis Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Novartis Therapeutic Nuclear Medicines Product Offerings
7.10.5 Novartis Recent Development
7.11 Siemens
7.11.1 Siemens Company Information
7.11.2 Siemens Introduction and Business Overview
7.11.3 Siemens Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Siemens Therapeutic Nuclear Medicines Product Offerings
7.11.5 Siemens Recent Development
7.12 NTP Radioisotopes
7.12.1 NTP Radioisotopes Company Information
7.12.2 NTP Radioisotopes Introduction and Business Overview
7.12.3 NTP Radioisotopes Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 NTP Radioisotopes Therapeutic Nuclear Medicines Product Offerings
7.12.5 NTP Radioisotopes Recent Development
7.13 ANSTO
7.13.1 ANSTO Company Information
7.13.2 ANSTO Introduction and Business Overview
7.13.3 ANSTO Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 ANSTO Therapeutic Nuclear Medicines Product Offerings
7.13.5 ANSTO Recent Development
7.14 Polatom
7.14.1 Polatom Company Information
7.14.2 Polatom Introduction and Business Overview
7.14.3 Polatom Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Polatom Therapeutic Nuclear Medicines Product Offerings
7.14.5 Polatom Recent Development
7.15 China Isotope & Radiation
7.15.1 China Isotope & Radiation Company Information
7.15.2 China Isotope & Radiation Introduction and Business Overview
7.15.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 China Isotope & Radiation Therapeutic Nuclear Medicines Product Offerings
7.15.5 China Isotope & Radiation Recent Development
7.16 Dongcheng Pharma
7.16.1 Dongcheng Pharma Company Information
7.16.2 Dongcheng Pharma Introduction and Business Overview
7.16.3 Dongcheng Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.16.4 Dongcheng Pharma Therapeutic Nuclear Medicines Product Offerings
7.16.5 Dongcheng Pharma Recent Development
7.17 Saide Bio
7.17.1 Saide Bio Company Information
7.17.2 Saide Bio Introduction and Business Overview
7.17.3 Saide Bio Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
7.17.4 Saide Bio Therapeutic Nuclear Medicines Product Offerings
7.17.5 Saide Bio Recent Development
8 Industry Chain Analysis
8.1 Therapeutic Nuclear Medicines Industrial Chain
8.2 Therapeutic Nuclear Medicines Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Therapeutic Nuclear Medicines Sales Model
8.5.2 Sales Channel
8.5.3 Therapeutic Nuclear Medicines Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

Contact US

Ankit Jain - Director, Global Digital Marketing

QY Research, INC.
India Office -
315Work Avenue, Raheja Woods, Kalyani Nagar,
Pune, Maharashtra 411006, India
Web - https://www.qyresearch.in
Email- ankit@qyresearch.com

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

This release was published on openPR.